Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
ClaimsFiler is reminding investors who lost over $100,000 in Ultragenyx Pharmaceutical Inc. (RARE) to file lead plaintiff applications by April 6, 2026, in a securities class action lawsuit. The lawsuit alleges Ultragenyx failed to disclose material information between August 3, 2023, and December 26, 2025. This action stems from a significant stock price drop after the company announced its Phase 3 Orbit and Cosmic studies for setrusumab in Osteogenesis Imperfecta failed to meet their primary endpoints, leading to plans for substantial expense reductions.
Ultragenyx Pharmaceutical Inc. Grants 22,917 Restricted Stock Units to Newly Hired Non-Executive Officers
Ultragenyx Pharmaceutical Inc. has granted 22,917 restricted stock units (RSUs) to six new non-executive officers as an employment inducement, in accordance with Nasdaq Listing Rule 5635(c)(4). These RSUs will vest over four years, with 25% vesting annually, contingent on continuous employment. The move aims to attract and retain talent in developing therapies for rare diseases, though it could raise concerns about shareholder dilution.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported granting 22,917 restricted stock units to six new non-executive officers. These awards were made under the company's Employment Inducement Plan as an incentive for their employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest over four years, with 25% vesting annually, contingent on continuous employment.
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Faruqi & Faruqi, LLP is reminding investors of Ultragenyx Pharmaceutical (NASDAQ: RARE) about the April 6, 2026 deadline to act as lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Ultragenyx and its executives made misleading statements regarding clinical trial results for its drug setrusumab, which led to significant stock price drops following negative study announcements in July and December 2025. Investors who suffered losses exceeding $50,000 are encouraged to contact the firm to discuss their legal options.
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline For Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has issued a notice to investors of Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) regarding a class action securities lawsuit. The lawsuit seeks to recover losses for investors affected by alleged securities fraud between August 3, 2023, and December 26, 2025. Investors have until April 6, 2026, to request to be appointed as lead plaintiff.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
Pomerantz LLP has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for alleged securities fraud. The lawsuit advises investors who suffered losses to contact Danielle Peyton, with a deadline of April 6, 2026, to apply as Lead Plaintiff. The action follows significant stock price drops in response to negative clinical trial results for the Company's osteogenesis imperfecta drug, UX143 (setrusumab).
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - RARE
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), inviting investors who purchased stock between August 3, 2023, and December 26, 2025, to seek appointment as lead plaintiff by April 6, 2026. The lawsuit alleges that Ultragenyx made misleading statements regarding its Phase III Orbit study for Osteogenesis Imperfecta, failing to disclose risks and ultimately reporting that the study did not achieve statistical significance, leading to significant stock price drops. Investors are encouraged to contact Robbins Geller to learn more about leading the lawsuit.
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors
The Portnoy Law Firm has announced a class-action lawsuit on behalf of investors in Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE) who purchased securities between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made false and misleading statements regarding the efficacy of its drug, setrusumab, and failed to disclose risks associated with its Phase III Orbit study, particularly concerning the lack of a placebo control group in previous Phase II trials. Investors have until April 6, 2026, to file a lead plaintiff motion.
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 - RARE
Levi & Korsinsky, LLP has reminded investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) about a pending class action securities lawsuit. The lawsuit seeks to recover losses for investors affected by alleged securities fraud between August 3, 2023, and December 26, 2025, claiming the company made misleading statements regarding its setrusumab drug. Ultragenyx's stock significantly declined after announcing that its Phase III Orbit and Cosmic studies did not meet primary endpoints, leading to a 42.32% drop in one day.
RARE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Faruqi & Faruqi, LLP has reminded Ultragenyx Pharmaceutical (RARE) investors of the April 6, 2026, deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Ultragenyx made misleading statements and failed to disclose risks regarding its Phase III Orbit study for Osteogenesis Imperfecta, which subsequently failed to meet its primary endpoints, causing significant drops in stock price. Investors who purchased RARE securities between August 3, 2023, and December 26, 2025, and suffered losses are encouraged to contact the firm.
The Gross Law Firm Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 - RARE
The Gross Law Firm is reminding Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shareholders who purchased shares between August 3, 2023, and December 26, 2025, about a pending class action lawsuit. The lawsuit alleges that Ultragenyx made misleading statements regarding its drug setrusumab's potential, particularly concerning its ability to reduce fracture rates, leading to a significant stock price drop after negative Phase III study results were announced. Investors have until April 6, 2026, to seek lead plaintiff appointment.
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors
ClaimsFiler is reminding Ultragenyx Pharmaceutical Inc. (RARE) investors who sustained losses exceeding $100,000 to file as lead plaintiffs by April 6, 2026, in a securities class action lawsuit. The lawsuit alleges that Ultragenyx failed to disclose material information, specifically regarding the failure of its Phase 3 Orbit and Cosmic studies for setrusumab, which led to a significant 42% stock price drop. Investors who purchased shares between August 3, 2023, and December 26, 2025, are affected.
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP – Company Announcement - FT.com
A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Investors who purchased common stock between August 3, 2023, and December 26, 2025, are affected, with a deadline of April 6, 2026, to file for lead plaintiff status. The lawsuit alleges that Ultragenyx made misleading statements and omissions regarding the drug setrusumab and its Phase III Orbit study.
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors
ClaimsFiler is reminding Ultragenyx Pharmaceutical Inc. (RARE) investors who suffered losses exceeding $100,000 that they have until April 6, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Ultragenyx and its executives failed to disclose material information regarding the failure of its Phase 3 Orbit and Cosmic studies, which led to a significant 42% drop in the company's stock price.
Ultragenyx Pharmaceutical Inc. SEC 10-K Report
Ultragenyx Pharmaceutical Inc. has released its annual 10-K report, detailing financial performance, business operations, and strategic initiatives in the rare disease therapy sector. Despite revenue growth to $673 million, the company reported a net loss of $575 million due to significant R&D and administrative expenses. Ultragenyx continues to expand its product portfolio and geographic reach while addressing financial, regulatory, and market risks.
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Ultragenyx Pharmaceutical Inc. (RARE) on behalf of investors who purchased common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made misleading statements and omissions regarding its drug, setrusumab, and the Phase III Orbit study results. Investors have until April 6, 2026, to apply for lead plaintiff status.
Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE
Robbins LLP is reminding Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stockholders who purchased shares between August 3, 2023, and December 26, 2025, about a class action lawsuit. The lawsuit alleges that Ultragenyx misled investors regarding the efficacy of setrusumab in its Phase III Orbit and Cosmic studies, contending that the drug's increase in bone density did not correlate with a decrease in fracture rates. The company's stock price dropped significantly by over 42% after it announced that the studies failed to meet primary endpoints.
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 - RARE
Levi & Korsinsky, LLP reminds investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) about a pending class action lawsuit. The lawsuit seeks to recover losses for investors affected by alleged securities fraud between August 3, 2023, and December 26, 2025, concerning misleading statements about the potential of setrusumab. Investors have until April 6, 2026, to request to be appointed as lead plaintiff.
Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by Aberdeen Group plc
Aberdeen Group plc significantly increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 94.3% in Q3, now holding 973,656 shares valued at $29.3 million. Despite substantial institutional ownership, Ultragenyx faces challenges including multiple securities-fraud class-action lawsuits and a recent 10% workforce reduction aimed at achieving profitability by 2027. Analysts maintain a "Moderate Buy" consensus, though some have lowered price targets due to these near-term headwinds and an EPS miss in the latest quarter.
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC has announced a class action securities lawsuit against Ultragenyx Pharmaceutical Inc. (RARE) on behalf of investors who suffered losses between August 3, 2023, and December 26, 2025. The lawsuit follows a 42% share price drop after the company revealed that its Phase 3 studies for the drug setrusumab failed to significantly reduce fracture rates in patients with osteogenesis imperfecta.
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors
Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for investors who purchased common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made false statements regarding its Phase III Orbit study for Osteogenesis Imperfecta, leading to significant stock price drops after the studies failed to achieve statistical significance. Investors have until April 6, 2026, to seek appointment as lead plaintiff.
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: A 190% Potential Upside Awaits Investors
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a biopharmaceutical company focused on rare genetic diseases, with a current market cap of $1.98 billion and a stock price of $20.52. Despite current unprofitability and a bearish technical outlook, analysts project a potential upside of 190.69% with an average target price of $59.65, driven by revenue growth and a strong pipeline. The stock is currently oversold, suggesting a potential rebound for investors willing to undertake biotechnology risks.
Ultragenyx Pharmaceutical's (RARE) Neutral Rating Reaffirmed at Wedbush
Wedbush has reaffirmed its "Neutral" rating for Ultragenyx Pharmaceutical (RARE), setting a price target of $25.00, suggesting a potential upside of approximately 21.5%. Despite missing EPS estimates, Ultragenyx reported revenue of $207M, beating expectations. The company also saw insider selling activity, with CFO Howard Horn selling 3,081 shares in December.
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors
Robbins Geller Rudman & Dowd LLP has announced that investors who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, have until April 6, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that Ultragenyx and its executives made false and misleading statements regarding the efficacy of setrusumab in treating Osteogenesis Imperfecta, particularly concerning its Phase III Orbit study results. The firm states that Ultragenyx stock prices fell significantly after announcements that the study failed to achieve statistical significance on its primary endpoints.
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding purchasers of Ultragenyx Pharmaceutical Inc. common stock between August 3, 2023, and December 26, 2025, that they have until April 6, 2026, to move for lead plaintiff in a securities fraud lawsuit. The lawsuit alleges that Ultragenyx made misleading statements regarding its Phase III Orbit and Cosmic Studies for setrusumab, which failed to demonstrate a decrease in annualized fracture rates for Osteogenesis Imperfecta patients despite increasing bone density. Investors who bought stock during this period may be entitled to compensation.
RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Faruqi & Faruqi, LLP is reminding investors of Ultragenyx Pharmaceutical (RARE) who purchased securities between August 3, 2023, and December 26, 2025, about the April 6, 2026, deadline to seek lead plaintiff status in a securities class action lawsuit. The lawsuit alleges that Ultragenyx made misleading statements and failed to disclose critical information regarding the efficacy of its setrusumab drug in Phase III clinical trials, leading to significant stock price drops when trial failures were announced. Investors suffering losses are encouraged to contact Faruqi & Faruqi to discuss their legal options.
Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE)
Ultragenyx Pharmaceutical (RARE) is receiving favorable sentiment due to its strong rare disease pipeline and anticipated regulatory milestones. Analysts like Ram Selvaraju and Eliana Merle have issued "Buy" and "Overweight" ratings, respectively, with significant price targets, driven by the company's potential for profitability by 2027 and robust fundamentals in the biotech sector. The company focuses on developing therapies for rare genetic diseases and is actively pursuing gene therapy trials.
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
Rosen Law Firm has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made misleading statements regarding its Phase III Orbit and Cosmic Studies for setrusumab (UX 143), concealing that the increase in bone density did not correlate with a decrease in annualized fracture rates. Investors are encouraged to secure counsel before the April 6, 2026, deadline to serve as lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Ultragenyx Pharmaceutical Inc. (RARE) on behalf of investors who purchased securities between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made misleading statements regarding the effectiveness and risks associated with its setrusumab drug for Osteogenesis Imperfecta, particularly regarding the Phase III Orbit study results. Investors who suffered losses are encouraged to join the case by April 6, 2026, with no upfront cost.
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Ultragenyx Pharmaceutical Inc. (RARE) on behalf of investors who purchased common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made misleading statements and omissions regarding its drug, setrusumab, and its Phase III Orbit study results. Investors have until April 6, 2026, to file for lead plaintiff status.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - RARE
The Rosen Law Firm is encouraging investors of Ultragenyx Pharmaceutical Inc. with losses over $100K to join a securities class action lawsuit. The lawsuit alleges that Ultragenyx made misleading statements regarding its Phase III Orbit and Cosmic Studies for setrusumab, failing to disclose that while the drug increased bone density, it did not correlate to a decrease in fracture rates. Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, have until April 6, 2026, to move the court to serve as lead plaintiff.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its Q4 2025 earnings, reporting a miss on EPS expectations at $-1.29. The company outlined a strategic restructuring plan, including a 10% workforce reduction, aimed at achieving profitability by 2027 while advancing its pipeline of rare disease treatments. Key updates included a resubmission setback for UX111 (MPS IIIA), progress in Angelman syndrome and Glycogen Storage Disease Type Ia programs, and strong commercial growth of existing products.
Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shared positive long-term clinical data for UX111, an investigational gene therapy for Sanfilippo syndrome Type A, showing significant reductions in cerebrospinal fluid heparan sulfate and improvements in cognitive, communication, and motor skills. The data, with up to 8.5 years of follow-up, supported the resubmission of a Biologics License Application (BLA) to the US FDA in January 2026 for accelerated approval, with a PDUFA action date expected in Q3 2026. The therapy demonstrated a favorable safety profile and robust treatment effects, particularly in younger patients.
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for alleged violations of the Securities Exchange Act. Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, and suffered substantial losses, have until April 6, 2026, to seek appointment as lead plaintiff. The lawsuit claims Ultragenyx made misleading statements and failed to disclose risks regarding its Phase III Orbit and Cosmic studies, which ultimately did not achieve statistical significance for their primary endpoints, leading to significant stock price drops.
Ultragenyx Pharmaceutical Class Action Update
Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit alleging false or misleading statements regarding its Osteogenesis Imperfecta (OI) study, which led to significant stock price drops following negative trial results. Investors who purchased stock between August 3, 2023, and December 26, 2025, have until April 6, 2026, to seek lead plaintiff status. Despite these legal challenges, analysts hold mixed views, with some maintaining an "Overweight" rating while others have lowered price targets due to regulatory hurdles and a recent workforce reduction.
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has notified investors in Ultragenyx Pharmaceutical Inc. (RARE) about a class action securities lawsuit. The lawsuit alleges securities fraud between August 3, 2023, and December 26, 2025, during which the company's shares dropped significantly after its Phase 3 Orbit and Cosmic studies for setrusumab failed to meet statistical significance for reducing fracture rates. Investors who suffered losses have until April 6, 2026, to request to be appointed as lead plaintiff.
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE), informing investors of an April 6, 2026, application deadline to serve as lead plaintiff. The lawsuit alleges securities fraud between August 3, 2023, and December 26, 2025, following a significant stock price drop after two Phase 3 studies for its drug setrusumab failed to meet their primary endpoints. Investors who suffered losses are encouraged to contact KSF for more information.
Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A
Ultragenyx (RARE) recently announced positive long-term data for its investigational UX111 gene therapy for Sanfilippo syndrome Type A, showing sustained reductions in cerebrospinal fluid heparan sulfate and significant improvements in cognitive, communication, and motor skills. The company resubmitted its Biologics License Application (BLA) to the FDA in January 2026, seeking accelerated approval with a PDUFA action date expected in Q3 2026. This gene therapy demonstrated favorable safety and more robust treatment effects in younger patients, while older children maintained critical functional abilities longer than untreated peers.
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – RARE
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) on behalf of investors who suffered losses between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made misleading statements regarding its drug setrusumab's potential, particularly concerning its ability to reduce fracture rates, leading to a significant stock price drop after negative Phase III study results were announced. Investors have until April 6, 2026, to request to be appointed as lead plaintiff.
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
Ultragenyx (RARE) reported a wider-than-expected loss of $1.29 per share in Q4 2025, though revenues increased 25% year-over-year to $207 million, surpassing estimates. For the full year 2025, total revenues grew 20% to $673 million, but the net loss per share was also wider than anticipated. The company provided 2026 financial guidance and announced a strategic restructuring plan, including a 10% workforce reduction, to achieve profitability by 2027.
ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
Rosen Law Firm has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) on behalf of investors who purchased common stock between August 3, 2023, and December 26, 2025. Investors are encouraged to secure counsel and must move the Court to serve as lead plaintiff by April 6, 2026. The lawsuit alleges that Ultragenyx made false or misleading statements regarding the potential of its drug setrusumab, claiming damages for investors when the true details emerged.
ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
Rosen Law Firm has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) on behalf of investors who purchased common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made misleading statements and concealed material adverse facts regarding the potential of its drug setrusumab, specifically concerning its correlation with a decrease in annualized fracture rates. Investors are encouraged to secure counsel before the April 6, 2026, deadline to serve as lead plaintiff.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
Pomerantz LLP has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for alleged securities fraud. The lawsuit stems from significant stock price drops following the company's announcements regarding its Phase 3 Orbit study results in July and December 2025. Investors who purchased Ultragenyx securities during the Class Period have until April 6, 2026, to seek appointment as Lead Plaintiff.
Ultragenyx Pharmaceutical Inc. Sued for Securities Law
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is facing a class action securities lawsuit initiated by Levi & Korsinsky, LLP. The lawsuit alleges securities fraud between August 3, 2023, and December 26, 2025, claiming the company made misleading statements regarding its drug setrusumab's potential. This comes after Ultragenyx announced on December 29, 2025, that its Phase III studies for setrusumab failed to achieve statistical significance, leading to a significant 42.32% drop in its stock price.
Ultragenyx Pharmaceutical Q4 Earnings Report: What Investors Need to Know
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced its Q4 earnings, reporting an EPS of $-1.29 against an estimate of $-1.18, missing by -9.32%. Revenue increased by $42.12 million year-over-year. The company's past performance shows a missed EPS in the previous quarter, which led to a 1.82% drop in share price the following day.
Ultragenyx: Q4 Earnings Snapshot
Ultragenyx Pharmaceutical Inc. (RARE) reported a Q4 loss of $129 million, or $1.29 per share, falling short of analyst expectations of $1.20 per share. However, the company's revenue for the quarter reached $207 million, exceeding Street forecasts of $202.9 million. For the full year, Ultragenyx recorded a loss of $575 million on revenues of $673 million.
Investors in Ultragenyx Pharmaceutical Inc. Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights - RARE
The Gross Law Firm is notifying shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) about a class action lawsuit. Investors who purchased shares between August 3, 2023, and December 26, 2025, are encouraged to contact the firm regarding their rights, as the company's stock dramatically declined after Phase III studies for its drug setrusumab failed to meet primary endpoints. The deadline to seek lead plaintiff appointment is April 6, 2026.
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of Ultragenyx Pharmaceutical, Inc. investors who purchased securities between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made misleading statements regarding its drug setrusumab's effects on Osteogenesis Imperfecta patients and downplayed risks associated with its Phase III Orbit study results. Investors have until April 6, 2026, to file a lead plaintiff motion.
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE). The lawsuit alleges that Ultragenyx made misleading statements regarding its setrusumab drug and its Phase III Orbit study, failing to disclose risks associated with the interim analysis. Investors who purchased securities between August 3, 2023, and December 26, 2025, have until April 6, 2026, to file a lead plaintiff motion.
Investors in Ultragenyx Pharmaceutical Inc. Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights - RARE
The Gross Law Firm has issued a notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) regarding a class action lawsuit. The lawsuit alleges that Ultragenyx made misleading statements about its drug setrusumab's potential, particularly concerning its Phase III Orbit and Cosmic studies, which failed to achieve statistical significance. Shareholders who purchased RARE shares between August 3, 2023, and December 26, 2025, are encouraged to contact the law firm by April 6, 2026, to discuss their rights, as the stock price dramatically declined after the negative study results.
